

# INFECTIOUS DISEASES I PANEL

---

## EDITORIAL BOARD LIAISON

Marisel Segarra-Newnham, Pharm.D.,  
MPH, FCCP, BCPS  
*Clinical Pharmacy Specialist, Infectious Diseases*  
Pharmacy Service  
Veterans Affairs Medical Center  
West Palm Beach, Florida  
*Clinical Assistant Professor of Pharmacy Practice*  
University of Florida College of Pharmacy  
Gainesville, Florida

## HIV INFECTION AND AIDS

### Author

P. Brandon Bookstaver, Pharm.D., BCPS  
(AQ Infectious Diseases), AAHIVE  
*Associate Professor*  
Department of Clinical Pharmacy  
and Outcomes Sciences  
South Carolina College of Pharmacy  
University of South Carolina  
Columbia, South Carolina

### Reviewers

Patrick G. Clay, Pharm.D., FCCP, CCTI  
*Associate Professor*  
College of Medicine  
*Director of Clinical Research*  
Department of Clinical Research  
Kansas City University of Medicine and Bioscience  
Kansas City, Missouri

Jeffrey T. Sherer, Pharm.D., MPH, BCPS  
*Clinical Associate Professor*  
Department of Clinical Sciences and Administration  
University of Houston College of Pharmacy  
Houston, Texas

Nancy S. Yunker, Pharm.D., BCPS  
*Assistant Professor*  
Department of Pharmacotherapy and Outcomes Science  
Virginia Commonwealth University  
School of Pharmacy  
*Clinical Pharmacy Specialist, Adult Internal Medicine*  
Virginia Commonwealth University Health System  
Richmond, Virginia

## PRIMARY CARE IN HIV

### Author

Jason J. Schafer, Pharm.D., BCPS, AAHIVE  
*Assistant Professor*  
Department of Pharmacy Practice  
The Jefferson School of Pharmacy  
Thomas Jefferson University  
Philadelphia, Pennsylvania

### Reviewers

Pamela S. Belperio, Pharm.D., BCPS, AAHIVE  
*National Public Health Clinical Pharmacist*  
Office of Public Health/Population Health  
Department of Veterans Affairs  
Los Angeles, California

Marisel Segarra-Newnham, Pharm.D.,  
MPH, FCCP, BCPS  
*Clinical Pharmacy Specialist, Infectious Diseases*  
Pharmacy Service  
Veterans Affairs Medical Center  
West Palm Beach, Florida  
*Clinical Assistant Professor of Pharmacy Practice*  
University of Florida College of Pharmacy  
Gainesville, Florida

## TUBERCULOSIS

### Authors

Rocsanna Namdar, Pharm.D., BCPS  
*Assistant Professor*  
Department of Clinical Pharmacy  
Skaggs School of Pharmacy and  
Pharmaceutical Sciences  
University of Colorado Anschutz Medical Campus  
Aurora, Colorado

Charles A. Peloquin, Pharm.D., FCCP  
*Professor*  
College of Pharmacy  
*Director, Infectious Disease Pharmacokinetics Laboratory*  
Emerging Pathogens Institute  
University of Florida  
Gainesville, Florida

## Reviewers

Lisa C. Hutchison, Pharm.D., MPH, FCCP, BCPS  
*Professor*  
Pharmacy Practice  
University of Arkansas for Medical Sciences  
Little Rock, Arkansas

Douglas Slain, Pharm.D., FCCP, BCPS  
*Associate Professor*  
*Infectious Diseases Clinical Specialist*  
Department of Clinical Pharmacy  
West Virginia University School of Pharmacy  
Morgantown, West Virginia

*The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 9, Infectious Diseases I chapters:*

Nicola G. Dahl, Pharm.D.  
*Medical Writer*  
Kanab, Utah

Julia Elenbaas, Pharm.D.  
Anthem, Arizona

Dale Whitby, Pharm.D., BCPS  
*Managing Editor, Clinical Content*  
Elsevier/Gold Standard  
Midlothian, Virginia

# DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

---

*Consultancies:* P. Brandon Bookstaver (Johnson & Johnson [Ortho-McNeil]); Patrick G. Clay (GlaxoSmithKline [ViiV Healthcare], U.S. Food and Drug Administration, Koronis Pharmaceuticals); Joseph T. DiPiro (American Association of Colleges of Pharmacy, U.S. Food and Drug Administration, AACP); Shannon W. Finks (Novartis Pharmaceuticals); Brian A. Hemstreet (Conexus Health); Vanthida Huang (Astellas Pharma [Theravance Inc.], Ortho-McNeil); Lisa C. Hutchison (Arkansas Medicaid, Arkansas Foundation for Medical Care); Amy Pakyz (Ortho-McNeil), Jean A. Patel (University Health System Consortium); Michael Postelnick (Hospira); Michelle Richardson (Amgen, QualityMetric); David J. Ritchie (Pfizer, Astellas Pharma); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, Annals of Pharmacotherapy); Jeffrey T. Sherer (Sturge-Weber Foundation); Douglas Slain (Wyeth)

*Stock Ownership:* Lisa M. Avery (Merck); Katherine H. Chessman (Procter & Gamble [spouse or significant other]); Joseph T. DiPiro (Bristol Myers Squibb, Pfizer); Lisa C. Hutchison (Cardinal Health)

*Royalties:* Joseph T. DiPiro (McGraw-Hill, ASHP); Lisa C. Hutchison (ASHP)

*Grants:* Jarrett R. Amsden (Astellas Pharma); P. Brandon Bookstaver (Cubist Pharmaceuticals, Astellas Pharma, Merck & Co); Kevin W. Garey (Merck); Jennifer Hagerman (Gilead); Brian A. Hemstreet (AstraZeneca); Anne L.

Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Michael B. Kays (Ortho-McNeil); Michael E. Klepser (Gilead); Jennifer Le (NIH/NIAID, Cubist, Memorialcare Foundation); Craig A. Martin (Pfizer); Amy Pakyz (Cubist, ViroPharma, AHRQ); Charles A. Peloquin (Jacobus Pharmaceuticals); Marc H. Scheetz (Cubist, TheraDoc, Inc., BioCryst Pharmaceuticals)

*Honoraria:* Lisa M. Avery (Astellas Pharma); Elias B. Chahine (Optimer Pharmaceuticals, Inc.); Clarence Chant (Hospira Canada and Drug Intelligence Inc.); Vanthida Huang (Forest, Cubist); Lisa C. Hutchison (American College of Clinical Pharmacy, American Society of Health-System Pharmacists); Michael B. Kays (Astellas Pharma, Merck); Michael E. Klepser (Cubist), Jennifer Le (Pfizer); Jean A. Patel (Northwestern Feinberg School of Medicine Physician Assistant Program, Scottsdale Institute) Michelle Richardson (Amgen); David J. Ritchie (Astellas Pharma, Cubist)

*Other:*

*Nothing to Disclose:* David T. Bearden; Pamela Belperio; Adam B. Jackson; Emilie Karpiuk; Marianne McCollum; Ryan Moenster; Rocsanna Namdar; Phillip S. Owen; Jason J. Schafer; Jamie S. Winner; Nancy Yunker

**ROLE OF ACCP:** ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmacy Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

**ROLE OF BPS:** The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at [www.bpsweb.org/recertification/general.cfm](http://www.bpsweb.org/recertification/general.cfm).

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties  
2215 Constitution Avenue NW  
Washington, DC 20037  
(202) 429-7591  
[www.bpsweb.org](http://www.bpsweb.org)